Feb 18, 2009 - GTx, Inc. announced today that the USFDA has accepted for filing and review the New Drug Application for toremifene 80 mg, an oral selective estrogen receptor modulator, which GTx seeks to market for the prevention of bone fractures in men with prostate cancer on androgen deprivation therapy (ADT).
The details can be read here.
No comments:
Post a Comment